Brazil takes first concrete step in assessing the economic impact of regulation
This article was originally published in Clinica
Executive Summary
The heads of Brazilian healthcare regulatory agency Anvisa are close to receiving a draft framework for the first national assessment of the economic impact of its activities. The group set up to draft the project is expected to report to Anvisa's directorate by the end of this month, according to a statement issued by Anvisa following a conference involving consultants on the project, held on August 11, in Brasilia. This is the first stage in a wider programme to assess the impact of regulation across all industrial sectors, which Anvisa was chosen to pilot (see Clinica No 1318, p 2).
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.